Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial
Titel:
Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial
Auteur:
Frenel, J.S. Kim, J.W. Aryal, N. Asher, R. Berton, D. Vidal, L. Pautier, P. Ledermann, J.A. Penson, R.T. Oza, A.M. Korach, J. Huzarski, T. Pignata, S. Colombo, N. Park-Simon, T.W. Tamura, K. Sonke, G.S. Freimund, A.E. Lee, C.K. Pujade-Lauraine, E.